Similar articles

• No cash to implement NICE, health authorities tell MPs. The National Institute for Clinical Excellence.

  Burke K. Burke K. BMJ. 2002 Feb 2;324(7332):258. doi: 10.1136/bmj.324.7332.258. BMJ. 2002. PMID: 11936127 Free PMC article. No abstract available.
• The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.

  Detournay B. Detournay B. Value Health. 2002 Jan-Feb;5(1):1-2. doi: 10.1046/j.1524-4733.2002.51001.x. Value Health. 2002. PMID: 11873378 No abstract available.
• Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

  Garattini L, Ghislandi F, Da Costa MR. Garattini L, et al. Pharmacoeconomics. 2015 Dec;33(12):1241-4. doi: 10.1007/s40273-015-0322-7. Pharmacoeconomics. 2015. PMID: 26293887 Review. No abstract available.
• Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

  Clegg A, Bryant J, Milne R. Clegg A, et al. Health Technol Assess. 2000;4(9):i-iv, 1-101. Health Technol Assess. 2000. PMID: 10944743 No abstract available.
• Glatiramer acetate for multiple sclerosis.

  [No authors listed] [No authors listed] Drug Ther Bull. 2001 Jun;39(6):41-3. doi: 10.1136/dtb.2001.39641. Drug Ther Bull. 2001. PMID: 11432030 Review.